Here are four things to know:
1. Abbott Laboratories agreed to divest Abbott Medical Optics to Johnson & Johnson for nearly $4.325 billion in cash.
2. Through the deal, Johnson & Johnson will purchase Abbott’s ophthalmic products which include products for cataract surgery, laser vision correction and consumer eye health.
3. The ophthalmology industry is heating up as other companies, including Parsippany-Troy Hills, N.J.-based Allergan, build on its eye care efforts. Allergan recently acquired RetroSense Therapeutics in a $60 million deal.
4. Johnson & Johnson expects to close the deal at the end of the first quarter next year.
More healthcare news:
Analysts give SCA $54.75 price target — 4 notes
Nemours Alfred I. duPont Hospital for Children opens $45M pediatric center, includes ASC: 4 things to know
Aurora Health Care opens $38M Germantown Health Center, equipped with ASC: 5 takeaways
